Generic Prialt Availability

Prialt is a brand name of ziconotide, approved by the FDA in the following formulation(s):

PRIALT (ziconotide acetate - injectable;intrathecal)

  • Manufacturer: JAZZ PHARMS INTL
    Approval date: December 28, 2004
    Strength(s): 100MCG/1ML (100MCG/ML) [RLD], 500MCG/20ML (25MCG/ML) [RLD], 500MCG/5ML (100MCG/ML) [RLD]

Has a generic version of Prialt been approved?

No. There is currently no therapeutically equivalent version of Prialt available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prialt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method of producing analgesia
    Patent 5,364,842
    Issued: November 15, 1994
    Inventor(s): Justice; Alan & Singh; Tejinder & Gohil; Kishor C. & Valentino; Karen L.
    Assignee(s): Neurex Corporation
    A method of producing analgesia and enhancing opiate analgesia is disclosed. The method includes administering TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue, as evidenced by the peptide's ability to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind to omega-conopeptide MVIIA binding sites present in neuronal tissue.
    Patent expiration dates:
    • December 30, 2016
      ✓ 
      Patent use: TREATMENT OF PAIN
    • December 30, 2016
      ✓ 
      Patent use: ANALGESIA
  • Stable omega conopetide formulations
    Patent 5,795,864
    Issued: August 18, 1998
    Inventor(s): Amstutz; Gary Arthur & Bowersox; Stephen Scott & Gohil; Kishorchandra & Adriaenssens; Peter Isadore & Kristipati; Ramasharma
    Assignee(s): Neurex Corporation
    Disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.
    Patent expiration dates:
    • June 27, 2015
      ✓ 
      Drug product
  • Method for administering omega-conopeptide
    Patent 8,653,033
    Issued: February 18, 2014
    Assignee(s): Jazz Pharmaceuticals International Limited
    The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
    Patent expiration dates:
    • October 1, 2024
      ✓ 
      Patent use: ANALGESIA
    • October 1, 2024
      ✓ 
      Patent use: TREATMENT OF PAIN
  • Method for administering omega-conopeptide
    Patent 8,765,680
    Issued: July 1, 2014
    Assignee(s): Jazz Pharmaceuticals International Limited
    The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
    Patent expiration dates:
    • October 1, 2024
      ✓ 
      Patent use: ANALGESIA
    • October 1, 2024
      ✓ 
      Patent use: TREATMENT OF PAIN

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)